Industry perspective
Siasun Robot&Automation Co.Ltd(300024) auxiliary surgery has outstanding advantages and is expected to set off a revolution in traditional surgery and medical treatment. Compared with traditional surgery, Siasun Robot&Automation Co.Ltd(300024) assisted surgery has the advantages of less trauma, more flexible operation, higher accuracy and stability, shorter doctor learning cycle and lower radiation exposure of patients and doctors. Surgery Siasun Robot&Automation Co.Ltd(300024) has been favored by a large number of doctors all over the world. Since the birth of the industry, there have been Siasun Robot&Automation Co.Ltd(300024) new types of surgery. At present, endoscopic surgery Siasun Robot&Automation Co.Ltd(300024) , orthopedic surgery Siasun Robot&Automation Co.Ltd(300024) , pan vascular surgery Siasun Robot&Automation Co.Ltd(300024) , natural lumen surgery Siasun Robot&Automation Co.Ltd(300024) and percutaneous puncture surgery Siasun Robot&Automation Co.Ltd(300024) have emerged. In the future, the promotion of Siasun Robot&Automation Co.Ltd(300024) auxiliary surgery in hospital terminals is expected to set off a revolution in medical surgery in the world.
The global surgical Siasun Robot&Automation Co.Ltd(300024) market is growing rapidly, and China is still in its infancy. The global surgical Siasun Robot&Automation Co.Ltd(300024) market scale is growing rapidly. In 2020, the global surgical Siasun Robot&Automation Co.Ltd(300024) market scale will reach US $8.3 billion. Although there are a large number of patients in China and there may be a large number of conventional minimally invasive operations that need surgery Siasun Robot&Automation Co.Ltd(300024) , the scale of China’s surgery Siasun Robot&Automation Co.Ltd(300024) market in 2020 is only US $425 million, accounting for 5.1% of the global market, and the penetration rate is significantly lower than that of the US and EU markets. China’s surgery Siasun Robot&Automation Co.Ltd(300024) market has great potential in the future.
The policy supports the innovation of high-end medical devices, and the coverage of surgical Siasun Robot&Automation Co.Ltd(300024) medical insurance is expected to be gradually expanded. In recent years, the government has formulated many policies to encourage the development and innovation of high-end medical devices such as surgery Siasun Robot&Automation Co.Ltd(300024) . Surgery Siasun Robot&Automation Co.Ltd(300024) as a key product to change the mode of surgical treatment in the future, it is expected to continue to be encouraged and supported by national policies in the future. In particular, domestic surgery Siasun Robot&Automation Co.Ltd(300024) enterprises are expected to stand out in the market. Some regions in China have begun to incorporate Siasun Robot&Automation Co.Ltd(300024) assisted surgery into medical insurance. In the future, with the increase of medical insurance coverage and the listing of domestic surgery Siasun Robot&Automation Co.Ltd(300024) , the high cost factors restricting the promotion of Siasun Robot&Automation Co.Ltd(300024) are expected to be gradually solved.
Siasun Robot&Automation Co.Ltd(300024) has a wide range of applications, and different types of products have great potential. 1) As the largest market segment, endoscopic surgery Siasun Robot&Automation Co.Ltd(300024) can be used in urology, gynecology, general surgery and other fields. American intuitive surgery company occupies an absolute dominant position. The volume of surgery in the Chinese market is increasing, but the penetration rate is only 0.5% in 2020, and there is still great potential for demand. 2) In orthopaedic surgery Siasun Robot&Automation Co.Ltd(300024) , joint replacement surgery is widely used, and surgery in China is still in its infancy; Spinal surgery Siasun Robot&Automation Co.Ltd(300024) has long-term market potential, and some domestic enterprises have emerged in recent years. 3) Pan vascular surgery Siasun Robot&Automation Co.Ltd(300024) has a huge potential volume of operations in the world, but the Chinese operation has not yet started. 4) Transluminal surgery Siasun Robot&Automation Co.Ltd(300024) is still in its early stage, and globally approved products are still scarce. 5) Percutaneous puncture surgery Siasun Robot&Automation Co.Ltd(300024) in 2020, the number of operations in China was only 22600, with a penetration rate of 1.4%. Many enterprises have launched layout outside China. Different types of Siasun Robot&Automation Co.Ltd(300024) products have great potential in China, and more new surgical Siasun Robot&Automation Co.Ltd(300024) will appear in the world in the future. Surgical Siasun Robot&Automation Co.Ltd(300024) is expected to lead the wave of domestic device innovation.
Investment advice
Industry strategy: Based on the clinical advantages of Siasun Robot&Automation Co.Ltd(300024) assisted surgery and the support of national policies for Innovation Medical Management Co.Ltd(002173) devices, we are optimistic about the future application potential of Siasun Robot&Automation Co.Ltd(300024) surgery in the medical field and the high growth of the industry in the future. At the same time, the competition pattern in the field of Siasun Robot&Automation Co.Ltd(300024) surgery in China is good, and domestic leading enterprises are expected to stand out in the future, Surgery Siasun Robot&Automation Co.Ltd(300024) is expected to become a revolutionary product in the medical industry.
Key companies: it is recommended to pay attention to the advantageous enterprises with rich product layout and leading R & D progress among domestic enterprises, such as minimally invasive Siasun Robot&Automation Co.Ltd(300024) , Weigao surgery Siasun Robot&Automation Co.Ltd(300024) , Tinavi Medical Technologies Co.Ltd(688277) , Yida health, Weisente medical under pelt, etc.
Risk statement
The enterprise’s product R & D progress is less than expected; Siasun Robot&Automation Co.Ltd(300024) the operation cost is too high or included in the medical insurance reimbursement is less than expected; The progress of product application and promotion does not meet expectations; Medical malpractice risk.
